Clinical Trial Update: Chronic Pain Master Protocol (CPMP): A Study of LY3556050 in Participants With Diabetic Peripheral Neuropathic Pain [Phase 2]

View source ↗

Summary

Phase 2 trial update for LY3556050 in diabetic peripheral neuropathic pain; study terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetic Peripheral Neuropathic Pain

Drugs mentioned

• LY3556050 (LY3556050)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Diabetic Peripheral Neuropathic Pain | Phase 2 | Status: TERMINATED | Results posted: 2023-11-02